The global Phase 3 POLARIX study showed that previously untreated DLBCL patients receiving Pola, rituximab (Rit), cyclophosphamide, doxorubicin, and prednisone (Pola‐R‐CHP) had significantly higher progression‐free survival rates than those who received Rit, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) [7]. Here, DDIT3 is linked to diffuse large B-cell lymphoma.